Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 15 de 15
Filtrer
1.
Brain Behav Immun Health ; 15: 100265, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-34589771

RÉSUMÉ

Microglia are tissue-resident macrophages of the central nervous system (CNS), and important for CNS development and homeostasis. In the adult CNS, microglia monitor environmental changes and react to tissue damage, cellular debris, and pathogens. Here, we present a gene expression profile of purified microglia isolated from the rhesus macaque, a non-human primate, that consists of 666 transcripts. The macaque microglia transcriptome was intersected with the transcriptional programs of microglia from mouse, zebrafish, and human CNS tissues, to determine (dis)similarities. This revealed an extensive overlap of 342 genes between the transcriptional profile of macaque and human microglia, and showed that the gene expression profile of zebrafish is most distant when compared to other species. Furthermore, an evolutionair core based on the overlapping gene expression signature from all four species was identified. This study presents a macaque microglia transcriptomics profile, and identifies a gene expression program in microglia that is preserved across species, underscoring their CNS-tailored tissue macrophage functions as innate immune cells with CNS-surveilling properties.

2.
Oncogene ; 34(25): 3305-14, 2015 Jun.
Article de Anglais | MEDLINE | ID: mdl-25151961

RÉSUMÉ

Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrP(C)) triggers a large number of trophic effects in the nervous system. We found that both PrP(C) and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrP(C) and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrP(C) binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrP(C) binding site (HOP230-245) abrogates this effect. PrP(C) knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrP(C)-HOP engagement is a promising approach for GBM therapy.


Sujet(s)
Troubles de la cognition/prévention et contrôle , Cognition , Glioblastome/anatomopathologie , Glioblastome/physiopathologie , Protéines du choc thermique HSP70/métabolisme , Protéines du choc thermique HSP90/métabolisme , Prions/métabolisme , Séquence d'acides aminés , Animaux , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Troubles de la cognition/complications , Troubles de la cognition/métabolisme , Femelle , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Glioblastome/complications , Glioblastome/traitement médicamenteux , Protéines du choc thermique HSP70/génétique , Protéines du choc thermique HSP90/génétique , Humains , Mâle , Souris , Données de séquences moléculaires , Grading des tumeurs , Fragments peptidiques/composition chimique , Fragments peptidiques/pharmacologie , Fragments peptidiques/usage thérapeutique , Liaison aux protéines/effets des médicaments et des substances chimiques , Analyse de survie , Tests d'activité antitumorale sur modèle de xénogreffe
3.
Mol Genet Metab ; 106(3): 287-300, 2012 Jul.
Article de Anglais | MEDLINE | ID: mdl-22658377

RÉSUMÉ

Pompe disease is a genetic disorder resulting from a deficiency of lysosomal acid alpha-glucosidase (GAA) that manifests as a clinical spectrum with regard to symptom severity and rate of progression. In this study, we used microarrays to examine gene expression from the muscle of two cohorts of infantile-onset Pompe patients to identify transcriptional differences that may contribute to the disease phenotype. We found strong similarities among the gene expression profiles generated from biceps and quadriceps, and identified a number of signaling pathways altered in both cohorts. We also found that infantile-onset Pompe patient muscle had a gene expression pattern characteristic of immature or regenerating muscle, and exhibited many transcriptional markers of inflammation, despite having few overt signs of inflammatory infiltrate. Further, we identified genes exhibiting correlation between expression at baseline and response to therapy. This combined dataset can serve as a foundation for biological discovery and biomarker development to improve the treatment of Pompe disease.


Sujet(s)
Glycogénose de type II/génétique , Transcription génétique , alpha-Glucosidase/génétique , Âge de début , Enfant , Enfant d'âge préscolaire , Femelle , Expression des gènes , Glycogénose de type II/métabolisme , Humains , Nourrisson , Nouveau-né , Mâle , Muscles squelettiques/métabolisme , Phénotype , alpha-Glucosidase/métabolisme
4.
Mitochondrion ; 11(1): 48-53, 2011 Jan.
Article de Anglais | MEDLINE | ID: mdl-20643228

RÉSUMÉ

Mitochondrial DNA (mtDNA) alterations and their clinical and pathological implications have been analyzed in several human malignancies. A marked decrease in mtDNA copy number along with the increase in malignancy was observed in diffusely infiltrating astrocytomas (24 WHO grade II, 18 grade III, and 78 grade IV or GBM) compared to non-neoplastic brain tissues, being mostly depleted in GBM. Although high relative gene expression levels of mtDNA replication regulators (mitochondrial polymerase catalytic subunit (POLG), transcription factors A (TFAM), B1 (TFB1M) and B2 (TFB2M)) were detected, it cannot successfully revert the mtDNA depletion observed in our samples. On the other hand, a strong correlation among the expression levels of mitochondrial transcription factors corroborates with the TFAM role in the direct control of TFB1M and TFB2M during initiation of mtDNA replication. POLG expression was related to decreased mtDNA copy number, and its overexpression associated with TFAM expression levels also have an impact on long-term survival among GBM patients, interpreted as a potential predictive factor for better prognosis.


Sujet(s)
Astrocytome/mortalité , Astrocytome/anatomopathologie , ADN mitochondrial/génétique , DNA-directed DNA polymerase/métabolisme , Dosage génique , Facteurs de transcription/métabolisme , Astrocytome/génétique , DNA Polymerase gamma , Réplication de l'ADN , ADN mitochondrial/métabolisme , Protéines de liaison à l'ADN/génétique , Protéines de liaison à l'ADN/métabolisme , DNA-directed DNA polymerase/génétique , Régulation de l'expression des gènes , Humains , Methyltransferases/génétique , Methyltransferases/métabolisme , Mitochondries/génétique , Mitochondries/métabolisme , Protéines mitochondriales/génétique , Protéines mitochondriales/métabolisme , Analyse de survie , Taux de survie , Facteurs de transcription/génétique , Transcription génétique
5.
Arq. neuropsiquiatr ; 69(2b): 328-331, 2011. tab
Article de Anglais | LILACS | ID: lil-588093

RÉSUMÉ

Medulloblastoma is the most common childhood malignant tumor of central nervous system, but it may also occur in adults. It presents high invasive growth with spreading of tumor cells into the leptomeningeal space along the neuroaxis early in the course of the disease. Extraneural metastases are rare but frequently lethal, occurring only in 1 to 5 percent of patients, and are related, in the most of cases, to the presence of ventriculoperitoneal shunt. Here we characterize the clinical profile of five cases of medulloblastoma with systemic spreading of tumor cells, also comparing them to cases already described in the literature.


O meduloblastoma é o tumor maligno mais frequente do sistema nervoso central na infância, mas também pode ocorrer em adultos. Ele apresenta crescimento altamente invasivo com disseminação de células tumorais ao longo do neuroeixo precocemente no curso da doença. Metástases extraneurais são raras mas frequentemente letais, ocorrendo apenas em 1 a 5 por cento dos pacientes, e estão relacionadas, na maioria dos casos, a presença de derivação ventriculperitoneal. Neste artigo ,apresentamos o perfil de cinco casos de meduloblastoma com disseminção sistêmica das células tumorais, comparando-os com os casos já descritos na literatura.


Sujet(s)
Adulte , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Tumeurs du cervelet/anatomopathologie , Médulloblastome/secondaire , Tumeurs de l'abdomen/secondaire , Tumeurs de la moelle osseuse/secondaire , Études de suivi , Tumeurs du poumon/secondaire , Tumeurs du bassin/secondaire
6.
Proc Natl Acad Sci U S A ; 106(39): 16752-7, 2009 Sep 29.
Article de Anglais | MEDLINE | ID: mdl-19805368

RÉSUMÉ

Cell surface proteins are excellent targets for diagnostic and therapeutic interventions. By using bioinformatics tools, we generated a catalog of 3,702 transmembrane proteins located at the surface of human cells (human cell surfaceome). We explored the genetic diversity of the human cell surfaceome at different levels, including the distribution of polymorphisms, conservation among eukaryotic species, and patterns of gene expression. By integrating expression information from a variety of sources, we were able to identify surfaceome genes with a restricted expression in normal tissues and/or differential expression in tumors, important characteristics for putative tumor targets. A high-throughput and efficient quantitative real-time PCR approach was used to validate 593 surfaceome genes selected on the basis of their expression pattern in normal and tumor samples. A number of candidates were identified as potential diagnostic and therapeutic targets for colorectal tumors and glioblastoma. Several candidate genes were also identified as coding for cell surface cancer/testis antigens. The human cell surfaceome will serve as a reference for further studies aimed at characterizing tumor targets at the surface of human cells.


Sujet(s)
Biologie informatique , Protéines membranaires/génétique , Antigènes de surface/génétique , Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/métabolisme , Lignée cellulaire tumorale , Tumeurs colorectales/génétique , Bases de données génétiques , Épigenèse génétique , Variation génétique , Glioblastome/génétique , Humains , Protéines membranaires/métabolisme
7.
Clin Exp Rheumatol ; 27(3): 519-26, 2009.
Article de Anglais | MEDLINE | ID: mdl-19604449

RÉSUMÉ

OBJECTIVE: To assess MHC I and II expressions in muscle fibres of juvenile dermatomyositis (JDM) and compare with the expression in polymyositis (PM), dermatomyositis (DM) and dystrophy. PATIENTS AND METHODS: Forty-eight JDM patients and 17 controls (8 PM, 5 DM and 4 dystrophy) were studied. The mean age at disease onset was 7.1+/-3.0 years and the mean duration of weakness before biopsy was 9.4+/-12.9 months. Routinehistochemistry and immunohistochemistry (StreptABComplex/HRP) for MHC I and II (Dakopatts) were performed on serial frozen muscle sections in all patients. Mann-Whitney, Kruskal Wallis, chi-square and Fisher's exact statistical methods were used. RESULTS: MHC I expression was positive in 47 (97.9%) JDM cases. This expression was observed independent of time of disease, corticotherapy previous to muscle biopsy and to the grading of inflammation observed in clinical, laboratorial and histological parameters. The expression of MHC I was similar on JDM, PM and DM, and lower in dystrophy. On the other hand, MHC II expression was positive in just 28.2% of JDM cases and was correlated to histological features as inflammatory infiltrate, increased connective tissue and VAS for global degree of abnormality (p<0.05). MHC II expression was similar in DM/PM and lower in JDM and dystrophy, and it was based on the frequency of positive staining rather than to the degree of the MCH II expression. CONCLUSIONS: MHC I expression in muscle fibres is a premature and late marker of JDM patient independent to corticotherapy, and MHC II expression was lower in JDM than in PM and DM.


Sujet(s)
Dermatomyosite/métabolisme , Antigènes HLA/métabolisme , Muscles squelettiques/métabolisme , Marqueurs biologiques/métabolisme , Biopsie , Enfant , Enfant d'âge préscolaire , Études transversales , Dermatomyosite/diagnostic , Dermatomyosite/anatomopathologie , Diagnostic différentiel , Régulation de l'expression des gènes , Gènes MHC de classe I/génétique , Gènes MHC de classe II/génétique , Humains , Muscles squelettiques/anatomopathologie , Dystrophies musculaires/diagnostic , Dystrophies musculaires/métabolisme , Dystrophies musculaires/anatomopathologie , Polymyosite/diagnostic , Polymyosite/métabolisme , Polymyosite/anatomopathologie
8.
Int J Biol Markers ; 23(3): 140-6, 2008.
Article de Anglais | MEDLINE | ID: mdl-18949739

RÉSUMÉ

Epidermal growth factor receptor (EGFR) gene overexpression has been implicated in the development of many types of tumors, including glioblastomas, the most frequent diffusely infiltrating astrocytomas. However, little is known about the influence of the polymorphisms of EGFR on EGFR production and/or activity, possibly modulating the susceptibility to astrocytomas. This study aimed to examine the association of two EGFR promoter polymorphisms (c.-191C>A and c.-216G>T) and the c.2073A>T polymorphism located in exon 16 with susceptibility to astrocytomas, EGFR gene expression and survival in a case-control study of 193 astrocytoma patients and 200 cancer-free controls. We found that the variant TT genotype of the EGFR c.2073A>T polymorphism was associated with a significantly decreased risk of astrocytoma when compared with the AA genotype [sex- and age-adjusted odds ratio 0.51, 95% confidence interval 0.26-0.98]. No association of the two promoter EGFR polymorphisms (or combinations of these polymorphisms) and risk of astrocytomas, EGFR expression or survival was found. Our findings suggest that modulation of the EGFR c.2073A>T polymorphism could play a role in future therapeutic approaches to astrocytoma.


Sujet(s)
Astrocytome/génétique , Tumeurs du cerveau/génétique , Récepteurs ErbB/génétique , Polymorphisme génétique , Adulte , Sujet âgé , Allèles , Astrocytome/ethnologie , Tumeurs du cerveau/ethnologie , Brésil , Études cas-témoins , Femelle , Humains , Mâle , Adulte d'âge moyen , Odds ratio , Résultat thérapeutique
9.
Genet Mol Res ; 7(2): 295-304, 2008 Apr 08.
Article de Anglais | MEDLINE | ID: mdl-18551395

RÉSUMÉ

Cadherins are cell-to-cell adhesion molecules that play an important role in the establishment of adherent-type junctions by mediating calcium-dependent cellular interactions. The CDH1 gene encodes the transmembrane glycoprotein E-cadherin which is important in maintaining homophilic cell-cell adhesion in epithelial tissues. E-cadherin interacts with catenin proteins to maintain tissue architecture. Structural defects or loss of expression of E-cadherin have been reported as a common feature in several human cancer types. This study aimed to evaluate the expression of E-cadherin and their correlation with clinical features in microdissected brain tumor samples from 81 patients, divided into 62 astrocytic tumors grades I to IV and 19 medulloblastomas, and from 5 white matter non-neoplasic brain tissue samples. E-cadherin (CDH1) gene expression was analyzed by quantitative real-time polymerase chain reaction. Mann-Whitney, Kruskal-Wallis, Kaplan-Meir, and log-rank tests were performed for statistical analyses. We observed a decrease in expression among pathological grades of neuroepithelial tumors. Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than did neuroepithelial tumors. Expression of E-cadherin gene was higher in astrocytic than embryonal tumors (P = 0.0168). Low-grade malignancy astrocytomas (grades I-II) showed higher CDH1 expression than did high-grade malignancy astrocytomas (grades III-IV) and medulloblastomas (P < 0.0001). Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than grade I malignancy astrocytomas, considered as benign tumors (P = 0.0473). These results suggest that a decrease in E-cadherin gene expression level in high-grade neuroepithelial tumors may be a hallmark of malignancy in dedifferentiated tumors and that it may be possibly correlated with their progression and dissemination.


Sujet(s)
Cadhérines/génétique , Analyse de profil d'expression de gènes , Tumeurs neuroépitheliales/génétique , Adolescent , Adulte , Encéphale/métabolisme , Régulation de l'expression des gènes tumoraux , Humains , Adulte d'âge moyen , Tumeurs neuroépitheliales/anatomopathologie , ARN messager/génétique , ARN messager/métabolisme , RT-PCR
10.
Genet Mol Res ; 7(2): 371-8, 2008 Apr 22.
Article de Anglais | MEDLINE | ID: mdl-18551403

RÉSUMÉ

Diffuse infiltrating gliomas are the most common tumors of the central nervous system. Gliomas are classified by the WHO according to their histopathological and clinical characteristics into four classes: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma multiforme). Several genes have already been correlated with astrocytomas, but many others are yet to be uncovered. By analyzing the public SAGE data from 21 patients, comprising low malignant grade astrocytomas and glioblastomas, we found COL6A1 to be differentially expressed, confirming this finding by real time RT-PCR in 66 surgical samples. To the best of our knowledge, COL6A1 has never been described in gliomas. The expression of this gene has significantly different means when normal glia is compared with low-grade astrocytomas (grades I and II) and high-grade astrocytomas (grades III and IV), with a tendency to be greater in higher grade samples, thus rendering it a powerful tumor marker.


Sujet(s)
Astrocytome/génétique , Collagène de type VI/génétique , Analyse de profil d'expression de gènes , Astrocytome/anatomopathologie , Régulation de l'expression des gènes tumoraux , Humains , ARN tumoral/génétique , ARN tumoral/métabolisme , RT-PCR
11.
J Oral Rehabil ; 35(3): 191-5, 2008 Mar.
Article de Anglais | MEDLINE | ID: mdl-18254796

RÉSUMÉ

This study aimed to determine the frequency of temporomandibular disorder (TMD) signs in 68 individuals with cerebral palsy, aged between 3 and 23 years. TMD signs were evaluated according to the Research Diagnostic Criteria to assess temporomandibular joint sounds, lateral jaw deviation during opening and closing movements and limitation of maximum mouth opening (>40 mm). The frequency of TMD signs observed in the cerebral palsy group (46/68-67.6%) was higher than in the control group (17/68-25%). The clinical scenario of CP seems to make these individuals more prone to the development of TMD signs.


Sujet(s)
Paralysie cérébrale/complications , Troubles de l'articulation temporomandibulaire/complications , Adolescent , Adulte , Études cas-témoins , Loi du khi-deux , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Prévalence , Troubles de l'articulation temporomandibulaire/diagnostic
12.
Genet. mol. res. (Online) ; 7(2): 371-378, 2008. tab, ilus
Article de Anglais | LILACS | ID: lil-641002

RÉSUMÉ

Diffuse infiltrating gliomas are the most common tumors of the central nervous system. Gliomas are classified by the WHO according to their histopathological and clinical characteristics into four classes: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma multiforme). Several genes have already been correlated with astrocytomas, but many others are yet to be uncovered. By analyzing the public SAGE data from 21 patients, comprising low malignant grade astrocytomas and glioblastomas, we found COL6A1 to be differentially expressed, confirming this finding by real time RT-PCR in 66 surgical samples. To the best of our knowledge, COL6A1 has never been described in gliomas. The expression of this gene has significantly different means when normal glia is compared with low-grade astrocytomas (grades I and II) and high-grade astrocytomas (grades III and IV), with a tendency to be greater in higher grade samples, thus rendering it a powerful tumor marker.


Sujet(s)
Humains , Astrocytome/génétique , Collagène de type VI/génétique , Analyse de profil d'expression de gènes , Astrocytome/anatomopathologie , Régulation de l'expression des gènes tumoraux , RT-PCR , ARN tumoral
13.
Genet. mol. res. (Online) ; 7(2): 295-304, 2008.
Article de Anglais | LILACS | ID: lil-641010

RÉSUMÉ

Cadherins are cell-to-cell adhesion molecules that play an important role in the establishment of adherent-type junctions by mediating calcium-dependent cellular interactions. The CDH1 gene encodes the transmembrane glycoprotein E-cadherin which is important in maintaining homophilic cell-cell adhesion in epithelial tissues. E-cadherin interacts with catenin proteins to maintain tissue architecture. Structural defects or loss of expression of E-cadherin have been reported as a common feature in several human cancer types. This study aimed to evaluate the expression of E-cadherin and their correlation with clinical features in microdissected brain tumor samples from 81 patients, divided into 62 astrocytic tumors grades I to IV and 19 medulloblastomas, and from 5 white matter non-neoplasic brain tissue samples. E-cadherin (CDH1) gene expression was analyzed by quantitative real-time polymerase chain reaction. Mann-Whitney, Kruskal-Wallis, Kaplan-Meir, and log-rank tests were performed for statistical analyses. We observed a decrease in expression among pathological grades of neuroepithelial tumors. Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than did neuroepithelial tumors. Expression of E-cadherin gene was higher in astrocytic than embryonal tumors (P = 0.0168). Low-grade malignancy astrocytomas (grades I-II) showed higher CDH1 expression than did high-grade malignancy astrocytomas (grades III-IV) and medulloblastomas (P < 0.0001). Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than grade I malignancy astrocytomas, considered as benign tumors (P = 0.0473). These results suggest that a decrease in E-cadherin gene expression level in high-grade neuroepithelial tumors may be a hallmark of malignancy in dedifferentiated tumors and that it may be possibly correlated with their progression and dissemination.


Sujet(s)
Humains , Adolescent , Adulte , Adulte d'âge moyen , Cadhérines/génétique , Analyse de profil d'expression de gènes , Tumeurs neuroépitheliales/génétique , Cerveau/métabolisme , Régulation de l'expression des gènes tumoraux , Tumeurs neuroépitheliales/anatomopathologie , RT-PCR , ARN messager/génétique , ARN messager/métabolisme
14.
J Oral Rehabil ; 34(5): 323-8, 2007 May.
Article de Anglais | MEDLINE | ID: mdl-17441872

RÉSUMÉ

Cerebral palsy (CP) is one of the most frequent conditions encountered in the daily practice of dentists who treat special-needs patients and it seems that parafunctional oral habits are often present in such individuals. The aim of this study was to investigate the frequency of occurrence of parafunctional habits in individuals with CP. Sixty-five patients with CP were evaluated through a questionnaire and clinical observation, regarding the following habits: pacifier-sucking, finger-sucking, biting objects, tongue interposition, and bruxism. The results showed that nine (13.8%) patients presented with pacifier-sucking, four (6.1%) showed finger-sucking, 12 (18.4%) had the habit of biting objects, 27 (41.5%) presented with tongue interposition, and 24 (36.9%) had eccentric bruxism. The significance of the presence of oral parafunctional habits in individuals with CP, revealed in this study, justifies the need to establish protocols for adequate prevention and clinical intervention in order to minimize the deleterious consequences that may result from such habits.


Sujet(s)
Paralysie cérébrale/psychologie , Habitudes , Adolescent , Comportement de l'adolescent , Adulte , Bruxisme/physiopathologie , Enfant , Enfant d'âge préscolaire , Femelle , Succion digitale/effets indésirables , Succion digitale/psychologie , Humains , Mâle , Comportement de succion , Habitudes linguales/effets indésirables , Habitudes linguales/psychologie
15.
J Oral Rehabil ; 34(3): 195-200, 2007 Mar.
Article de Anglais | MEDLINE | ID: mdl-17302947

RÉSUMÉ

Myotonic dystrophy is a multisystemic disease with varying symptomatology. The aim of this study was to compare the maximal bite force and handgrip force in patients with molecular diagnosis of myotonic dystrophy with those in a group of healthy individuals. It was hypothesized that these forces were reduced in the patients in comparison with the control subjects. The bite and handgrip forces of 37 patients with molecular diagnosis of myotonic dystrophy and 37 control subjects matched regarding age and gender were measured using an electronic dynamometer. The bite and handgrip forces were significantly lower in the myotonic dystrophy patient group when compared with the healthy controls (P < 0.0001). There were no significant force differences between genders, right- or left-hand side of mastication or hands in the myotonic dystrophy patient group whereas such differences were found among the controls. There were moderate but significant correlations between bite and handgrip force in both groups (r = 0.43-0.59; P < 0.01). It was concluded that there were considerable differences between the myotonic dystrophy group and the control subjects regarding both bite force and handgrip force. The weakness of the masticatory and hand muscles may have various negative consequences for oral function and dental health in patients with myotonic dystrophy.


Sujet(s)
Force occlusale , Force de la main/physiologie , Dystrophie myotonique/physiopathologie , Adolescent , Adulte , Enfant , Santé de la famille , Femelle , Latéralité fonctionnelle/physiologie , Humains , Mâle , Muscles masticateurs/physiopathologie , Adulte d'âge moyen , Dynamomètre pour la mesure de la force musculaire , Facteurs sexuels
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...